Ticker >

Guj. Terce Lab share price

Gujarat Terce Laboratories Ltd.

BSE: 524314 SECTOR: Pharmaceuticals & Drugs  7200   9   0

56.97
-1.03 (-1.78%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 56.97

Today's Low

₹ 56.84

52 Week High

₹ 70.91

52 Week Low

₹ 16.65

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

42.27 Cr.

Enterprise Value

47.52 Cr.

No. of Shares

0.74 Cr.

P/E

83.88

P/B

6.44

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  8.85

CASH

2.03 Cr.

DEBT

7.27 Cr.

Promoter Holding

37.03 %

EPS (TTM)

₹  0.68

Sales Growth

16.57%

ROE

-21.71 %

ROCE

-14.81%

Profit Growth

-291.63 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Gujarat Terce Laboratories Ltd.

Vitfol Acolate Resplash Aziter Codimol TerfloraZ Tynol fungibeat

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year16.57%
3 Year7.61%
5 Year10.03%

Profit Growth

1 Year-291.63%
3 Year-282.24%
5 Year-243.91%

ROE%

1 Year-21.71%
3 Year-12.6%
5 Year-6.24%

ROCE %

1 Year-14.81%
3 Year-7.63%
5 Year-2.35%

Debt/Equity

1.0597

Price to Cash Flow

1583.28

Interest Cover Ratio

-3.0115054061547

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 37.03 0
Dec 2023 37.01 0
Sep 2023 36.78 0
Jun 2023 36.65 0
Mar 2023 36.45 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -4.21671929712291 days.

 Limitations

  • The company has shown a poor profit growth of -282.242800958865% for the Past 3 years.
  • The company has shown a poor revenue growth of 7.60880181534629% for the Past 3 years.
  • Company has a poor ROE of -12.5969943934541% over the past 3 years.
  • Company has a poor ROCE of -7.63117677075599% over the past 3 years
  • Company has low Interest coverage ratio of -3.0115054061547.
  • The company has a low EBITDA margin of -1.88853825680824% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 114.3099.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 11.91 12.89 10.72 12.03 13.02
Total Expenditure 11.79 13.09 11.84 11.49 12.17
Operating Profit 0.12 -0.2 -1.13 0.54 0.85
Other Income 0.08 0.1 0.08 0.08 0.08
Interest 0.14 0.17 0.17 0.2 0.16
Depreciation 0.07 0.16 0.09 0.09 0.09
Exceptional Items 0 0 0 0 0
Profit Before Tax 0 -0.42 -1.31 0.34 0.67
Tax 0 -1.22 0 0 0
Profit After Tax 0 0.8 -1.31 0.34 0.67
Adjusted EPS (Rs) -0.01 1.08 -1.76 0.45 0.91

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 31.03 37.54 25.18 40.13 46.78
Total Expenditure 30.54 36.86 27.95 39.02 48.95
Operating Profit 0.49 0.68 -2.77 1.12 -2.16
Other Income 0.32 0.29 0.8 0.31 0.35
Interest 0.25 0.29 0.39 0.4 0.72
Depreciation 0.21 0.24 0.18 0.28 0.36
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.35 0.44 -2.53 0.75 -2.89
Tax -0.09 0.16 -0.01 -0.13 -1.22
Net Profit 0.43 0.28 -2.52 0.87 -1.67
Adjusted EPS (Rs.) 0.58 0.37 -3.4 1.18 -2.25

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 7.42 7.42 7.42 7.42 7.42
Total Reserves 3.41 3.69 0.24 1.11 -0.56
Borrowings 0.13 0.16 0.42 2.3 1.46
Other N/C liabilities 1.71 1.79 1.9 3.04 2.07
Current liabilities 6.67 9.29 11.71 13.21 16.61
Total Liabilities 19.34 22.34 21.7 27.09 27
Assets
Net Block 2.06 2.29 2.45 4.29 3.99
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.29 0.27 0.27 0.27 0.27
Loans & Advances 2.44 2.54 2.55 2.65 2.29
Other N/C Assets 5.32 5.33 4.4 4.4 4.4
Current Assets 9.22 11.91 12.02 15.48 16.05
Total Assets 19.34 22.34 21.7 27.09 27
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 0.35 0.44 -2.52 0.75 -2.89
Adjustment 0.22 0.25 0.57 0.6 1.02
Changes in Assets & Liabilities -1.04 -2.17 1.94 -1.69 1.94
Tax Paid -0.13 -0.1 -0.15 -0.1 -0.04
Operating Cash Flow -0.61 -1.59 -0.16 -0.44 0.03
Investing Cash Flow -0.13 -0.27 -0.42 -2.37 0.62
Financing Cash Flow 0.2 1.72 1.83 1.53 -0.12
Net Cash Flow -0.55 -0.14 1.24 -1.28 0.52

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 36.45 36.65 36.78 37.01 37.03
aalap natubhai prajapati 0.65 0.65 0.72 0.72 0.72
abundant trade link priva... 14.50 14.50 14.50 14.50 14.50
amritbhai p. prajapati 0.42 0.42 0.42 0.42 0.42
natwarbhai parsottam praj... 8.07 8.27 8.31 8.55 8.57
prajapati manjulaben s 12.49 12.49 12.49 12.49 12.49
shachi ravi oza 0.10 0.10 0.10 0.10 0.10
shobhanaben natwarbhai pr... - - - - 0.22
shobhanaben natvarbhai pr... 0.22 0.22 0.22 0.22 -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 63.55 63.35 63.22 62.99 62.97
dheeraj kumar lohia 1.49 - 1.29 1.34 1.34
rishabh negi 1.01 1.01 1.01 1.01 1.01
sagar saxena - - - - 1.11
dhanpat mishrimal kothari... - - - 1.01 -
radhika rastogi 1.25 1.25 1.25 - -
satya prakash mittal (huf... 1.88 1.86 1.78 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

  • PresentationQ3FY24 10 Feb 2024
  • PresentationQ3FY22 1 Feb 2022
  • PresentationQ2FY22 9 Nov 2021

Company News

Guj. Terce Lab - Quaterly Results5 Feb 2024, 4:51PM Guj. Terce Lab - Quaterly Results5 Feb 2024, 4:51PM Guj. Terce Lab - Quaterly Results5 Feb 2024, 4:51PM Gujarat Terce Laboratories informs about loss of share certificate5 Jan 2024, 4:10PM Gujarat Terce Laboratories informs about loss of share certificate3 Jun 2023, 3:58PM Guj. Terce Lab - Quaterly Results13 May 2023, 7:17PM Guj. Terce Lab - Quaterly Results13 May 2023, 7:17PM Guj. Terce Lab - Quaterly Results31 Jan 2023, 5:40PM Guj. Terce Lab - Quaterly Results31 Jan 2023, 5:40PM Guj. Terce Lab - Quaterly Results31 Jan 2023, 5:40PM Gujarat Terce Laboratories informs about RPT disclosure25 Nov 2022, 5:08PM Gujarat Terce Laboratories informs about resignation of CS cum CO6 Sep 2022, 5:04PM Guj. Terce Lab - Quaterly Results5 Aug 2022, 5:18PM Guj. Terce Lab - Quaterly Results5 Aug 2022, 5:18PM Guj. Terce Lab - Quaterly Results5 Aug 2022, 5:18PM Gujarat Terce Laboratories informs about board meeting27 Jul 2022, 12:22PM Gujarat Terce Laboratories informs about compliance certificate7 Jul 2022, 4:50PM Gujarat Terce Laboratories informs about compliance certificate14 Apr 2022, 10:39AM Gujarat Terce Laboratories informs about outcome of board meeting24 Jan 2022, 2:47PM Guj. Terce Lab - Quaterly Results24 Jan 2022, 12:23PM Gujarat Terce Laboratories informs about typographical error in financial results29 Jul 2021, 12:22PM Gujarat Terce Laboratories informs about non-applicability of large corporate entity19 Jul 2021, 12:18PM Gujarat Terce Laboratories informs about clerical error2 Jul 2021, 3:55PM Gujarat Terce Laboratories informs about board meeting18 Jun 2021, 1:53PM Gujarat Terce Laboratories informs about outcome of board meeting7 Nov 2020, 3:23PM Gujarat Terce Laboratories informs about certificate9 Oct 2020, 3:03PM

Guj. Terce Lab Stock Price Analysis and Quick Research Report. Is Guj. Terce Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Guj. Terce Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Guj. Terce Lab cash from the operating activity was Rs 0.0267 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Guj. Terce Lab has a Debt to Equity ratio of 1.0597 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Guj. Terce Lab , the EPS growth was -291.624626368089 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Guj. Terce Lab has OPM of -4.62245497782291 % which is a bad sign for profitability.
     
  • ROE: Guj. Terce Lab have a poor ROE of -21.7133207767747 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Guj. Terce Lab is Rs 56.97. One can use valuation calculators of ticker to know if Guj. Terce Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Guj. Terce Lab
X